AdaptHealth Corp vs Anheuser-Busch Inbev SA — how do they compare? AdaptHealth Corp trades at $5.83 (market cap $753.09M), while Anheuser-Busch Inbev SA trades at $79.21 (market cap $159.01B). The key difference: Anheuser-Busch Inbev SA is far larger — about 211.1× AdaptHealth Corp's market cap, and Anheuser-Busch Inbev SA pays a 1.67% dividend while AdaptHealth Corp pays none. Which is the better fit depends on your goals.
| AHCO | BUD | |
|---|---|---|
Market Cap | $753.09M | $159.01B |
Sector | Health | Consumer Staples |
52-Week High | $13.38 | $86.48 |
52-Week Low | $5.22 | $57.93 |
Enterprise Value | $2.77B | $223.42B |
Dividend Yield | — | 1.67% |
Signals from Pluang's Aura AI — not financial advice
AdaptHealth Corp. (AHCO) trades at $5.74, up 9.96% in the last session, yet remains under pressure with a bearish technical signal and recent earnings misses. The company reported a Q2 2026 net loss of $228 million with a -6.82% margin, while selling its diabetes unit to focus on sleep and respiratory care. Valuation ratios show a low P/S of 0.23 and P/B of 0.55, but negative profitability metrics highlight operational challenges.
The outlook is mixed: analyst consensus is bullish with a $11 price target, but risks include ongoing losses, fraud investigations, and cost overruns in fixed-price contracts. Upside depends on successful business restructuring and margin improvement, while downside risks from legal and execution issues persist.
BUD trades at $79.3, down 4.56% on the day, with a bearish technical signal from moving averages and oscillators. Fundamentally, the company reported Q2 2026 EPS of $1.21, beating estimates, and maintains strong cash flow with $14.88B from operations in 2025. Revenue for 2025 was $59.32B, with net income margin improving to 11.52%. Recent news includes mixed institutional activity and Q2 earnings coverage highlighting volume growth and premium brand strength.
The outlook is supported by analyst consensus with a $90.17 price target and 57.78% buy ratings, but risks include recent shareholder share sales and competitive pressures. Earnings growth and deleveraging trends provide upside, while technical weakness near support at $79 requires monitoring for stability.
Trailing returns across standard periods
Latest headlines on both assets
AdaptHealth provides patient-centered healthcare-at-home solutions in the U.S. It offers medical equipment and supplies for sleep therapy, respiratory health, diabetes management, and general home wellness.
Read more on AHCO →Anheuser-Busch InBev is the largest brewer in the world and one of the world's top five consumer product companies, as measured by EBITDA. After the SABMiller acquisition, the company's portfolio now contains five of the top 10 beer brands by sales and 18 brands with retail sales over $1 billion. AB InBev was created by the 2008 merger of Belgium-based InBev and U.S.-based Anheuser-Busch. The firm holds a 62% economic interest in Ambev and in 2016 acquired SABMiller.
Read more on BUD →